- Clene’s CEO Rob Etherington and CFO Morgan Brown presented highlights and updates on the company’s pipeline – as well as answering questions from the audience
- Clene has conducted several clinical trials to test the efficacy of CNM-Au8(R), focusing on the diseases amyotrophic lateral sclerosis and multiple sclerosis
- CNM-Au8 has shown a favorable safety profile, with over 650 collective years of subject exposure without any major safety signals attributed to CNM-Au8
- Negotiations are underway to extend the cash runway into 2025, including potential licensing deals and the exercise of warrants that could bring in up to $130 million in additional capital for the company
Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently participated in the 72nd Emerging Growth Conference. EmergingGrowth.com is a leading independent small cap media portal that identifies companies with strong management teams, innovative products, focused strategy and overall potential for long-term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts. Clene’s CEO Rob Etherington and CFO Morgan Brown presented highlights and updates on the company’s pipeline – as well as answering questions from the audience.
The Emerging Growth Conference, moderated by award-winning journalist Ana Berry, is considered an effective way for public companies to engage with the investment community. Companies present new products, services, and make other announcements significant to their industry. During the event, Clene’s CEO presented the company’s groundbreaking asset, CNM-Au8, a suspension of gold nanocrystals designed to improve mitochondrial function and reduce oxidative stress. This novel treatment utilizes catalytic activity to enhance neuronal energy utilization, which is critical for maintaining brain function.
Neurodegenerative diseases such as ALS, Parkinson’s, and MS, are among the most challenging medical issues. These conditions involve the progressive degeneration of neurons. In ALS, degeneration of the motor neurons leads to compromised muscular functions, including breathing, swallowing, and motor skills. Despite various treatments, a definitive cure remains elusive. Clene is tackling this challenge with an innovative approach to neuroprotection.
Clene has conducted several clinical trials to test the efficacy of CNM-Au8, focusing on diseases like ALS and MS, and the results have been promising:
- RESCUE-ALS: A Phase 2 study involving 45 subjects showed significant improvements in survival rates and in delaying disease progression.
- HEALEY-ALS Platform Trial: This major study demonstrated a 70-90% risk reduction in death among participants, marking a significant breakthrough in ALS treatment.
- VISIONARY-MS Study: This study focused on MS patients with optic neuritis. Results indicated significant improvements in vision, cognition, and fine and gross motor skills, with continued benefits over time.
- Compassionate Use Program: Over 256 patients have participated in these programs, with many participants showing extended survival and improved quality of life compared to historical controls.
CNM-Au8 has shown a favorable safety profile, with over 650 collective years of subject exposure without any major safety signals. The most common side effects are mild to moderate, primarily gastrointestinal issues, and headaches.
Clene is preparing for a potential accelerated approval from the FDA, based on the promising data from its clinical trials. The company is also exploring partnerships and non-dilutive funding opportunities to support further development and commercialization of CNM-Au8.
According to Brown, as of the first quarter, Clene holds approximately $28 million in cash, with an average burn rate of $7 million per quarter. Negotiations are underway to extend the cash runway into 2025, including potential licensing deals and the exercise of warrants that could bring in up to $130 million in additional capital.
To watch a replay of Clene’s presentation at the Emerging Growth Conference, visit the conference’s YouTube at https://nnw.fm/5itnB.
For more information, visit the company’s website at www.Clene.com.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is powered by IBN
